Medicines Co (MDCO) Cancels Stock Offering Related to Pending Administrative Activity on Angiomax Patent
More News related to MDCO
- New Publication Shows Angiomax Significantly Reduces Initial Hospital Costs by $572 Per Patient Compared to Conventional Therapy in Moderate and High-Risk ACS Patients
- Morning Movers 10/22: Coventry Health (CVH) Sinks On Results, SanDisk (SNDK) Down After Offer Pulled; Apple (AAPL) Higher On EPS
- The Medicines Company (MDCO) Reports Q3 Loss of $0.25; Raises FY08 Sales Outlook, Cuts EPS Guidance
- The Medicines Company Reports Third Quarter 2008 Financial Results
- Poor Perioperative Blood Pressure Control Linked to 30-Day Morbidity and Mortality in Cardiac Surgery Patients
The Medicines Company (NASDAQ: MDCO) is 6% higher this morning after the company said it has determined not to proceed with its pending public offering of common stock at this time.
The company said based on new information learned at 5:30 p.m. on January 23, 2007, the Company believes that it is possible that some administrative activity may occur in the near term with respect to the Company's application for term extension for the principal patent covering the Company's product Angiomax. The Company does not know whether any definitive action will be taken or, if taken, whether such action will be favorable or unfavorable.
Related Categories
FDATrader Talk
Stocks Mentioned
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
